Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
1.2.1. T-Cell Lymphoma Market, by Region, 2019-2029 (USD Million)
1.2.2. T-Cell Lymphoma Market, by Lymphoma Type, 2019-2029 (USD Million)
1.2.3. T-Cell Lymphoma Market, by Therapy Type, 2019-2029 (USD Million)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global T-Cell Lymphoma Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global T-Cell Lymphoma Market Dynamics
3.1. T-Cell Lymphoma Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rise in Lymphoma Cancer Incidence
3.1.1.2. Advancements in T-cell Lymphoma-specific Therapies
3.1.1.3. Risk of Lymphoma due to Autoimmune Disorders
3.1.2. Market Challenges
3.1.2.1. High Cost of Treatment
3.1.2.2. Adverse Side Effects of Therapies
3.1.3. Market Opportunities
3.1.3.1. Uptake Of Premium-Priced Products and Immune Checkpoint Inhibitors
3.1.3.2. Launch Of Several Novel Therapies with Label Extension of Commercialized Products
Chapter 4. Global T-Cell Lymphoma Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global T-Cell Lymphoma Market, by Lymphoma Type
6.1. Market Snapshot
6.2. Global T-Cell Lymphoma Market by Lymphoma Type, Performance - Potential Analysis
6.3. Global T-Cell Lymphoma Market Estimates & Forecasts by Lymphoma Type 2019-2029 (USD Million)
6.4. T-Cell Lymphoma Market, Sub Segment Analysis
6.4.1. Peripheral T-cell Lymphoma
6.4.2. T-cell Lymphoblastic Lymphoma
Chapter 7. Global T-Cell Lymphoma Market, by Therapy Type
7.1. Market Snapshot
7.2. Global T-Cell Lymphoma Market by Therapy Type, Performance - Potential Analysis
7.3. Global T-Cell Lymphoma Market Estimates & Forecasts by Therapy Type 2019-2029 (USD Million)
7.4. T-Cell Lymphoma Market, Sub Segment Analysis
7.4.1. Radiotherapy
7.4.2. Chemotherapy
7.4.3. Immunotherapy
7.4.4. Stem Cell Transplantation
7.4.5. Other Types of Therapies
Chapter 8. Global T-Cell Lymphoma Market, Regional Analysis
8.1. T-Cell Lymphoma Market, Regional Market Snapshot
8.2. North America T-Cell Lymphoma Market
8.2.1. U.S. T-Cell Lymphoma Market
8.2.1.1. Lymphoma Type breakdown estimates & forecasts, 2019-2029
8.2.1.2. Therapy Type breakdown estimates & forecasts, 2019-2029
8.2.2. Canada T-Cell Lymphoma Market
8.3. Europe T-Cell Lymphoma Market Snapshot
8.3.1. U.K. T-Cell Lymphoma Market
8.3.2. Germany T-Cell Lymphoma Market
8.3.3. France T-Cell Lymphoma Market
8.3.4. Spain T-Cell Lymphoma Market
8.3.5. Italy T-Cell Lymphoma Market
8.3.6. Rest of Europe T-Cell Lymphoma Market
8.4. Asia-Pacific T-Cell Lymphoma Market Snapshot
8.4.1. China T-Cell Lymphoma Market
8.4.2. India T-Cell Lymphoma Market
8.4.3. Japan T-Cell Lymphoma Market
8.4.4. Australia T-Cell Lymphoma Market
8.4.5. South Korea T-Cell Lymphoma Market
8.4.6. Rest of Asia Pacific T-Cell Lymphoma Market
8.5. Latin America T-Cell Lymphoma Market Snapshot
8.5.1. Brazil T-Cell Lymphoma Market
8.5.2. Mexico T-Cell Lymphoma Market
8.5.3. Rest of Latin America T-Cell Lymphoma Market
8.6. Rest of The World T-Cell Lymphoma Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Genmab AS
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Johnson & Johnson (Janssen Pharmaceuticals Inc.)
9.2.3. Mundipharma International, Limited
9.2.4. Bristol-Myers Squibb Company
9.2.5. Autolus Therapeutics PLC
9.2.6. Acrotech Biopharma, Inc.
9.2.7. Macopharma
9.2.8. Merck & Co. Inc.
9.2.9. F. Hoffmann-La Roche Ltd
9.2.10. Novartis AG
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption